U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07630545) titled 'A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.' on May 06.
Brief Summary: The goal of this study is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease.
Study Start Date: Nov. 30, 2023
Study Type: INTERVENTIONAL
Condition:
Parkinson's Disease (PD)
Mild to Moderate Parkinson's Disease
Early Stage Parkinson's Disease
Intervention:
DRUG: MTX325
MTX325
OTHER: Placebo
Placebo
Recruitment Status: RECRUITING
Sponsor: Mission Therapeutics
Published by HT Digital Content Services with permission from Health Daily Digest....